Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus ("HBV") infection. We are advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include the following programs: RNAi, Capsid Inhibitor, HBV RNA Destabilizers and additional pre-clinical assets.
January 4 2021
December 10 2020
November 16 2020